c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
Kenjiro Sawada(Gynecologic Oncology Group), Ernst Lengyel(University of Chicago), Amy R. Becker(Gynecologic Oncology Group), Muge Turkyilmaz, Nariyoshi Shinomiya(National Institute of Infectious Diseases), A. Reza Radjabi(Gynecologic Oncology Group), Emily O. Kistner, Hilary A. Kenny(Gynecologic Oncology Group), George F. Vande Woude(Van Andel Institute), Ravi Salgia(City Of Hope National Medical Center), S. Diane Yamada(University of Chicago), Maria Tretiakova(University of Washington)
Cited by 260
Related Papers
Ovarian Cancer Development and Metastasis
|American Journal Of Pathology|2010|1.7k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Decreased extra-renal urate excretion is a common cause of hyperuricemia
|Nature Communications|2012|690